NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

bioAffinity Technologies, Inc. (BIAF) Stock Analysis

bioAffinity Technologies, Inc. (BIAF) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

BIAF

$15.27

+$2.49 (+19.48%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BIAF with… →

BIAF Key Statistics

As of Sep 4, 2026
Trading
Open
$11.12
Previous Close
$12.78
Day's Range
10.90–20.35
52-Week Range
4.56–202.50
Volume
19.79M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.11
Valuation
Market Cap
$9.17M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.55
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.35
Financials (FY)
Revenue (FY)
$6.11M−34.76%
Net Income (FY)
−$14.91M
Profit marginThe share of revenue left as profit after all costs and taxes.
−257.33%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
600.74K
1-Year Return
+112.97%
Dividend and dates
Avg Volume
2.02M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BIAF Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+1194.07%
2025−95.68%
2024−38.14%
2023−8.06%
2022 (partial year)−80.72%

As of September 4, 2026.

BIAF Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$6.11M−$14.91M−244.1%
2024$9.36M−$9.04M−96.6%
2023$2.53M−$7.94M−313.4%
2022$4.80K−$8.15M−169771.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$6.11M$1.88M−$10.63M−$14.91M−244.1%
2024$9.36M$3.38M−$8.95M−$9.04M−96.6%
2023$2.53M$791.62K−$7.97M−$7.94M−313.4%
2022$4.80K$4.34K−$4.01M−$8.15M−169771.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BIAF Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricBIAFDiagnostics & Research medianvs median
P/S ratio1.554.990.3x the median
Profit margin−257.33%0.00%257.3 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

bioAffinity Technologies, Inc. (BIAF) is capitalised at $9.17M on the latest close. The company sits in the Healthcare sector, in the Diagnostics & Research industry. The company reports 57 employees.

Over the past 52 weeks the price has ranged from $4.56 to $202.50. BIAF last closed at $15.27 on September 4, 2026. That is +$2.49 (+19.48%) against the previous close. The latest close sits 234.87% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $6.11M. That is −34.76% against the prior fiscal year, when revenue was $9.36M. The same year closed with a net loss of $14.91M. Profit margin runs at −257.33%. That is 257.3 percentage points below the Diagnostics & Research median of 0%. Trailing earnings per share are −1.35.

Across the 4 fiscal years on file, revenue moves from $4.80K in 2022 to $6.11M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 1.55 times revenue. On price-to-sales that is 0.3 times the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +112.97%. Across 3 years the annualized return works out at −34.36%. The reported beta is −1.12. Daily returns over the trailing 4 years annualize to a volatility of 735.77%.

Growth & Income

No dividend is on file for BIAF.

2026 is still running; the price is +1,194.07% year to date. The strongest complete calendar year on file is 2023 at −8.06%; the weakest is 2025 at −95.68%. Of the 3 complete calendar years on file, 0 finished higher.

Peer Comparison

bioAffinity Technologies, Inc. (BIAF) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
bioAffinity Technologies, Inc. BIAF $9.17M —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. bioAffinity Technologies, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

Visit website →